Amgen Inc. with ticker code (AMGN) now have 23 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The target price High/Low ranges between $308.87 and $170.06 suggesting an average Analsyt target price of $255.40. Given that the stocks previous close was at $270.90 this would imply there is a potential downside of -5.7%. There is a 50 day moving average of $269.47 and the 200 day MA is $245.18. The company has a market cap of 143.96B. The stock price for the company is currently $269.00 USD
The potential market cap would be $135,725,803,156 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 19.12, revenue per share of $50.16 and a 7.86% return on assets.
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. The Company’s marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine) and AVSOLA (infliximab-axxq), Evenity, LumaKras, Nplate, XGeva, and others. The Company focuses on human therapeutics for the treatment of serious illness in the areas of inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience.
